Clinical Trials Logo

Filter by:
NCT ID: NCT02012179 Completed - Heart Failure Clinical Trials

SODIUM-HF: Study of Dietary Intervention Under 100 MMOL in Heart Failure

SODIUM-HF
Start date: March 24, 2014
Phase: Phase 3
Study type: Interventional

SODIUM-HF is a multicenter clinical trial in ambulatory patients with chronic HF to evaluate the efficacy of a low sodium containing diet on a composite clinical outcome composed of of all-cause mortality, cardiovascular hospitalizations and cardiovascular emergency department visits. The hypothesis of this study is that patients following a low-sodium containing diet will have fewer clinical events (fewer hospital readmissions or emergency department visits, longer survival) than those randomized to Usual Care.

NCT ID: NCT02011945 Completed - Clinical trials for Chronic Myeloid Leukemia

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

Start date: February 7, 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with Chronic Myeloid Leukemia.

NCT ID: NCT02010775 Completed - Clinical trials for Masseter Muscle Hypertrophy

Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy

Start date: January 20, 2014
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of a range of doses of botulinum toxin Type A (BOTOX®) for the treatment of patients with bilateral Masseter Muscle Hypertrophy (MMH).

NCT ID: NCT02010255 Completed - Clinical trials for Chronic HCV Infection

Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Start date: January 2014
Phase: Phase 2
Study type: Interventional

This study will evaluate ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) in participants with advanced liver disease or posttransplant and chronic genotype 1 or 4 hepatitis C virus (HCV) infection. - Cohort A: decompensated cirrhosis (advanced liver disease), no prior liver transplant; - Cohort B: post-liver transplant, with or without cirrhosis; - Group assignment within cohorts is based on severity of liver impairment at screening (Child-Pugh-Turcotte (CPT) score for participants with cirrhosis; fibrosis; or presence of disease for fibrosing cholestatic hepatitis (FCH) groups) - Randomization is 1:1 within groups to 12 or 24 weeks of LDV/SOF+RBV treatment.

NCT ID: NCT02010242 Completed - Clinical trials for Type 2 Diabetes Mellitus With Diabetic Nephropathy

Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

Start date: October 2013
Phase: Phase 2
Study type: Interventional

NADPH oxidase enzymes (NOX) have been implicated in the development of several diabetic complications including diabetic nephropathy. GKT137831 is the first in class NOX1/4 inhibitor. The primary objective of this study is to evaluate the efficacy of oral GKT137831 in patients with residual albuminuria despite maximal inhibition of the renin angiotensin aldosterone system.

NCT ID: NCT02009813 Completed - Obesity Clinical Trials

Hyperbaric Oxygen Therapy and Insulin Resistance (HOTAIR2) - Effect of One HBO Session.

HOTAIR2
Start date: March 2013
Phase: N/A
Study type: Interventional

Obesity is an epidemic in Western society and is the biggest risk factor for insulin resistance and type 2 diabetes. The investigators have recently shown that exposure to hyperbaric oxygen (HBO) leads to an increase insulin sensitivity in males ubjects and that this improvement can be measured in all men, not just those with diabetes. The aim of this study is to investigate the time course of this effect and explore the mechanisms involved. The investigators suspect that insulin sensitivity as measured by hyperinsulinaemic-euglycaemic clamp will be increased within the time-frame of one 2-hour hyperbaric oxygen exposure, and that the improvement will be measurable in females as well as males.

NCT ID: NCT02008357 Completed - Cognition Disorders Clinical Trials

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

A4
Start date: February 28, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).

NCT ID: NCT02007421 Completed - Cancer Clinical Trials

Study of the Prevention of Anal Cancer

SPANC
Start date: September 10, 2010
Phase: N/A
Study type: Interventional

SPANC stands for Study of the Prevention of Anal Cancer. There are more than 100 types of human papillomavirus (HPV). Some HPV types cause genital warts and other types cause more than 90% of anal cancer. Gay men are over 20 times more likely than others to develop anal cancer. SPANC is a study of anal (HPV) infection and related anal disease in gay men. The study will provide important information to guide the possible future introduction of anal cancer screening programs for gay men.

NCT ID: NCT02006732 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

Start date: November 2013
Phase: Phase 3
Study type: Interventional

The objective of this study is to assess the efficacy and safety of 12 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the Respimat inhaler) compared with tiotropium and placebo in patients with COPD.

NCT ID: NCT02006719 Completed - Adhesive Capsulitis Clinical Trials

Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder

AC
Start date: November 2013
Phase: Phase 2
Study type: Interventional

The objectives of this study are to assess the safety, effectiveness, and immunogenicity of AA4500 in the treatment of adhesive capsulitis.